Antibodies are becoming popular in the clinical practice for their use in the treatment of variety of clinical conditions such as cardiovascular and infectious diseases, autoimmune and CNS disorders, cancer and inflammation. Owing to their stable nature and high affinity for variety of biomolecules, antibodies are considered as best targeting and diagnostic reagents. In order to show their effects antibodies need to interact with elements of immune system and initiate the reaction cascade. Antibody engineering technique enabled the production of humanized antibodies which are more efficient and less immunogenic than chimeric and murine antibodies. More than 22 antibodies are currently available in the market for the treatment of cancer and immunological disorders. Novel technique of antibody-drug complex is proving more beneficial due to its selectivity towards the diseased cells. Some of the examples of therapeutic antibodies available in the market are ADL518 (rheumatoid arthritis), Aducanumab (Alzheimer’s disease), Alirocumab (hypercholesterolemia), Daclizumab (transplant rejection), Omalizumab (allergic asthma), Rituximab (cancer) etc.
Antibodies Market: Drivers and Restraints
Monoclonal antibodies are gaining more acceptance as a new therapeutic molecule due to high efficacy and lesser side effects. Advancements in technology and development of new molecules are believed to play a crucial role in the growth of global antibodies market during the forecast period. But the limited production capacity and restricted clinical applications of antibodies will always remain the greatest restraints for the global antibodies market.
Request Free Report Sample@ http://www.futuremarketinsights.com/reports/sample/rep-gb-1330
Antibodies Market: Segmentation
The global antibodies market has been classified on the basis of product type, type of disease, end user and geography.
Based on product type, the global antibodies market is divided into following:
- Monoclonal antibodies
- Polyclonal antibodies
- Antibody-drug complexes (ADCs)
- Antibody-based vaccines
Based on the disease type, the global antibodies market is divided into following:
- Cardiovascular diseases
- CNS disorders
- Autoimmune disorders
Based on the end user type, the global antibodies market is divided into following:
- Diagnostic centers
- Research institutes
Visit For TOC@ http://www.futuremarketinsights.com/toc/rep-gb-1330
Antibodies Market: Overview
Antibodies are majorly used in the treatment of cancers and immunological disorders as they are proving beneficial over the other chemotherapeutic agents. Monoclonal antibodies market segment holds the largest share in the market in 2014. Launching of novel antibody-drug complexes in coming future is expected to boost up the market volume. More than 30 antibody molecules and combination treatments are in the clinical trial pipeline. Some of them are expected to be launched in the global antibodies market in the forecast period such as Bortezomib, Eculizumab, VRC 606 to name a few. Antibodies for the treatment of infectious diseases has a least importance due to low penetration of large molecules inside the cells.
Antibodies Market: Regional Overview
Region wise, the global antibodies market is classified into regions namely, North America, Latin America, Western Europe, Eastern Europe, Asia-Pacific, Japan, Middle East and Africa. North America holds the largest share in the global antibodies market followed by Europe and Asia Pacific. Asia Pacific antibodies market is expected to grow at faster rate among other regions owing to the high patient population pool available and the increasing investments and collaborations in the biotechnology industry over the forecast period from 2016 to 2026. Increasing demands for the monoclonal antibodies in countries such as China and India to treat the infectious diseases is expected to increase the production of antibodies.
Full Report Analysis@ http://www.futuremarketinsights.com/reports/antibodies-market
Antibodies Market: Key Players
Some of the key players in global antibodies market are Sigma-Aldrich Corporation, Roche Ltd., Abcam plc, Sanofi S.A., Rockland Immunochemicals, AbbVie Inc., Amgen Inc., Thermo Fisher Scientific Inc., Novartis AG, Biogen-Idec Limited, MedImmune, GE Healthcare, Abnova Corporation and others.